News

We are very proud to welcome Professor Dominique Bagnard to the scientific Advisory Board of Rosetta Omics!
This marks the beginning of a strategic collaboration between Rosetta Omics and University of Strasbourg Ecole Supérieure de Biotechnologie Strasbourg INSERM Dr. Dominique Bagnard is a neuroscientist whose career has been dedicated to understanding the molecular mechanisms underlying brain development, neuronal connectivity, and neurodegenerative processes. His early research in neurobiology provided critical insights into cell signaling pathways and molecular interactions guiding axonal growth.
Building on this foundation, he expanded his expertise to the field of drug design, with the aim of translating fundamental discoveries into therapeutic strategies targeting neurological disorders and cancer. A central focus of his work has been the identification of molecular biomarkers that bridge basic neurobiology and applied drug discovery. By integrating molecular profiling with pharmacological approaches, Dr. Bagnard has contributed to the development of biomarker-driven strategies that enable both the evaluation of drug efficacy and the stratification of patient populations. His research combines advanced techniques in transcriptomics, proteomics, and molecular imaging to establish biomarker signatures with diagnostic, prognostic, and predictive value. Through this dual expertise in neurobiology and drug design, Dr. Bagnard has advanced the concept of biomarkers not only as indicators of disease progression but also as essential tools in guiding the development of targeted therapies. His multidisciplinary approach has fostered collaborations across academia, industry, and clinical settings, reinforcing the translational impact of his work in precision medicine.

We’re proud to announce that Kevin Adams has joined the eSAC Network as a Member. 🎉 The eSAC (European Systems and Artificial Cell) Network brings together leading scientists, innovators, and organizations advancing synthetic biology and artificial cell research across Europe and beyond. Kevin’s expertise in omics-driven research and systems biology makes him a perfect fit for this collaborative community, and we’re thrilled to see him representing Rosetta Omics on such an influential platform.

Proud to share another milestone in the partnership between Rosetta Omics and my alma mater, ESCP Business School!
This collaboration has already led to three International Consulting Projects (ICPs). Two completed and one ongoing. This is a unique opportunity where bright ESCP Executive Education & Business Solutions MBA Executives work hand-in-hand with companies like Rosetta Omics to solve real-world challenges. The ICP 2024–2025 team: Celine Mullet Eugen Pugatsch Mustapha Najmi Nick Lasse Beetz worked for almost a year to designing a go-to-market strategy for Rosetta Omics in the USA.Their work will play a key role in our international expansion and in bringing our AI-driven precision oncology solutions closer to cancer patients who urgently need them. This project was guided by Prof. Frederic Jallat, the academic director of the Advanced Master in Biopharmaceutical Management (MsM) and a KPMG Chair at ESCP Business School and supported by two committed ESCP Alumni mentors Stefano Scarafiotti Elena Ivanchenko
Thank you all for your dedication, creativity, and hard work! 🙏

🎭 the 2nd Day of the AI & Cancer 🎭 Sector. We are pleased to announce that our CEO, Dr. Wahid Awad, Ph.D. MBA participated in the Day of Filière Intelligence Artificielle & Cancers 📍 at the Ministère de l’économie et des Finances, Centre Pierre Mendès France (Paris Bercy). Dr. Awad: “As CEO of Rosetta Omics, I had the chance to participate in the first edition and I was excited to repeat the experience this year.” As in the first edition, this day was punctuated by interventions by public and private actors. This desire to bring people together reflects one of the association’s key missions: to encourage dialogue between all the stakeholders in the ecosystem, in order to enhance our national ecosystem by conducting oncology research projects that are both innovative and emblematic of the challenges of the health industry.

We are happy to share with our stakeholders, current and future partners, that we have completed our first Proof of Concept (POC) study in Colon Cancer. With approximately 20 million new cancer cases globally each year, the urgency for personalized, effective treatment options is higher than ever. Our innovative approach aims to enhance the prediction of treatment responses, providing physicians with critical insights to prescribe the most effective therapies for their patients at the right time to save lives and cost. Our mission is to revolutionize precision medicine, starting with cancer, by integrating multimodality data from patient tumors, clinical records, and advanced machine learning/AI algorithms. Additionally, we collaborate with pharmaceutical companies to discover new biomarkers and targets, aiding in patient stratification during clinical trials to expedite the development of safe and efficient cancer treatments.

We are happy to announce that our CEO Dr. Wahid Awad, Ph.D. MBA have been elected as an Executive Board Member (Membre exécutif du conseil administratif) at Medicen Paris Region! Dr. Awad is representing the PME (SMEs) of pharma, biotech, medtech, and diagnostics companies in Paris region ( Île-de-France) in the executive office of Medicen (bureau exécutif). Founded in 2005, the Medicen Paris Region global competitiveness cluster aims to position the Paris Region as a European industrial leader in diagnostic and therapeutic innovation and leading-edge health technologies, thus enabling it to become one of the global centres for translational medicine.

We are very happy to share that Professor Magali Svrcek, MD, PhD, a globally recognized expert in gastro-intestinal pathology and a pioneer in integrating artificial intelligence into pathology, has joined the Advisory Board of Rosetta Omics. Rosetta Omics is at the forefront of precision medicine in oncology, and Professor Svrcek’s extensive experience and groundbreaking research in AI-assisted pathology will be invaluable as we work together to revolutionize cancer diagnostics and personalized treatment strategies. Professor Svrcek, MD, PhD is a distinguished medical professional and academic with a profound expertise in pathology, particularly in the areas of gastro-intestinal diseases, including colorectal, gastric, and pancreatic cancers. She currently serves as a Full Professor at the Department of Pathology at Saint-Antoine Hospital, Paris, France, a position she has held since 2016.

We are happy to welcome Leonardo Cunha to the business Advisory Board of Rosetta Omics! 🎉 Leonardo brings extensive international leadership experience in M&A, business growth, strategy, sales & marketing, and internationalization, making him a strong addition to our Business Advisory Board. Throughout his career, he has held senior leadership roles in global industrial companies, where he successfully drove growth strategies, post-merger integrations, and market expansion across Europe, the Americas, and Asia. His academic background reflects both technical and business excellence: 📚 Engineering & Master’s degree from Universidade Estadual de Campinas (Unicamp) 📚 MBA from Northwestern University – Kellogg School of Management. Leonardo is also an early angel investor in Rosetta Omics, sharing our vision of transforming precision oncology through multiomics data, advanced mass spectrometry imaging, and AI-driven biomarker discovery.

Dr. Wahid Awad, CEO of Rosetta Omics participated in the 4th edition of the Viv Healthtech conference (an event dedicated to the health industry and technological innovation and organized by PROXIMUM 365 and financed by Région Nouvelle-Aquitaine and Bordeaux Métropole in Bordeaux where he participated at multiple interesting workshops, round tables and held multiple fruitful B2B meetings.

Our Founder & CEO Dr. Wahid Awad, Ph.D. MBA pitched Rosetta Omics to investors on December 11th in Bruges, Belgium, during the HealthTech Investor Summit! A big thank you to MEDVIA and the incredible team — Henk Joos, Rita Prota, Lindsay Nuytten — for organizing this amazing event, supported by 23 sponsors.

We are very happy to share with Rosetta Omics’ stakeholders: cancer patients, current and future partners, as well as current and future investors that we have successfully completed our second Proof of Concept (POC) study in Colon Cancer (CRC). A study three times as big as the first POC study and in a partnership with a major university hospital in France. This study showed great results and confirms our first study. Our innovative approach aims to enhance the prediction of treatment responses, providing physicians with critical insights to prescribe the most effective therapies for their patients at the right time to save lives and cost. Our mission is to revolutionize precision medicine, starting with cancer, by integrating spatial, multiomics, and multimodal data from patient tumors, clinical records, and proprietary machine learning/AI algorithms.

Rosetta Omics partnered at the RESI J.P. Morgan Healthcare week in San Francesco, California, USA.

We are very happy to welcome Anne De Landsheer to the Advisory Board of Rosetta Omics!
Anne brings a wealth of experience in Executive Search and Talent Management, with over 16 years in the Pharmaceutical industry and a decade of expertise in Life Sciences.
As the founder of PEAK LIFECYCLES HR – Europe & the US, Anne has demonstrated exceptional leadership, guiding businesses in Talent Acquisition and the development of senior executives across the US and Europe.
Her distinguished career includes:
✔️ Leading the Life Sciences Practice at Korn Ferry Executive Search.
✔️ Collaborating with early-stage and fast-growing organizations to build senior management teams.
✔️ Developing relationships with the Global Life Sciences community in Europe and the USA, including AESC, Jefferies, FACC-NY | French American Chamber of Commerce – New York, HTIDs by HealthTech For Care) and France Biotech.
✔️ Serving as a Board Member at REGEnLIFE, a cutting-edge Medtech company focused on brain-gut axis therapies.
Anne’s academic background further reflects her expertise:
📚 Master’s in Neurosciences from the UMass Boston
📚 MBA from ESCP Business School
📚 MS Management from ESSEC Business School.

We are thrilled to welcome Dr. Tanya Aneichyk to the Advisory Board of Rosetta Omics! 🎉

Tanya is a visionary leader in cancer omics data sharing and the founder & CEO of OmicsChart, where she drives innovation across Europe to accelerate drug development through real-world evidence and AI.

With a unique blend of technical expertise and commercial insight, Tanya’s journey from software engineering to bioinformatics has made her a trusted partner for biotech and pharma companies. She has helped numerous organizations identify, acquire, and integrate high-value biomarker and omics datasets to advance precision medicine.

At Harvard Medical School and Massachusetts General Hospital, her groundbreaking research on patient data analysis unlocked new possibilities in rare disease research, revitalizing a field that had seen little progress for decades.

Her deep expertise in omics biomarker discovery, AI-driven diagnostics, and pharma partnerships will be invaluable for Rosetta Omics as we continue our mission to revolutionize cancer care.

We are honored to announce the addition of Dr. Hatem Azim to the Scientific Advisory Board of Rosetta Omics! Dr. Azim brings unparalleled expertise in oncology and clinical development, with over two decades of groundbreaking work in cancer research and drug development.

👨‍⚕️ About Dr. Hatem Azim

Dr. Azim is a practicing medical oncologist and a clinical development consultant for EU and US oncology biotechs. He has previously held esteemed roles, including: Chief Medical Officer at Emergence Therapeutics. VP & Head of Clinical Development at Innate Pharma, France. He currently serves as: Senior Medical Oncologist at Cairo Cure Oncology Center. Senior Faculty Member at the European School of Oncology.

Academic Achievements:

🎓 Master’s Degree in Oncology – @University of Newcastle Upon Tyne (UK).

🎓 PhD in Oncology – Université libre de Bruxelles (Belgium).

🩺 Completed oncology training at the National Cancer Institute -Cairo University, and the @European Institute of Oncology, Milan.

🥼 Specialized in breast cancer during a fellowship at Institut Institut Jules Bordet, Brussels, where he also served as Scientific Director for the Breast Cancer Research Unit for three years.

Rosetta Omics, a cutting-edge deeptech startup revolutionizing oncology precision medicine, is thrilled to announce its membership and partnership with France Biotech. At Rosetta Omics, our mission is clear: to leverage the power of AI and multiomics data to drive advancements in cancer treatment. With this new partnership with France Biotech, a leading voice in the French biotech ecosystem, we’re poised to accelerate our impact and forge invaluable connections within the french healthcare industry. Joining France Biotech opens up a world of opportunities for collaboration, innovation, and growth. We’re eager to collaborate with fellow trailblazers, access resources, and contribute to the vibrant biotech community in France and beyond. Our journey to transform oncology is fueled by a passionate team dedicated to making a difference in the lives of patients worldwide. Together with France Biotech, we’re committed to driving forward the future of healthcare through groundbreaking research, technology, and partnerships.

We are pleased to share that in a partnership with my business school, ESCP Business School, a new ICP : International Consulting Project for 12 months has just started with Rosetta Omics as a Sponsor.
The photo is from the kick off meeting at Agoranov incubator in the center of Paris where we are based this Wednesday.
The international team of top tier executive MBA candidates from the executive MBA program ESCP Executive Education & Business Solutions, will carry out a Go-to-Market strategy project for 12 months.
The team will be working very closely with me and my team at Rosetta Omics under the supervision of professor Frederic Jallat (the Academic Director of the Advanced Master in Biopharmaceutical Management (MsM) and a KPMG Chair Research Associate at ESCP in Paris & London.
The project will be mentored by two high level executives from the healthcare industry who are alumni from the EMBA program of ESCP (ESCP Alumni).
The team of 5 consultants and Executive MBA candidates that were selected from 12 applicants are:
– Laila ROUGAIBI from Servier
– Celine Mullet from Fresenius Kabi
– PD Dr. Nick Lasse Beetz, MD from Charité – University Medicine Berlin
– Mustapha Najmi from Groupe Crédit Agricole
– Eugen Pugatsch from Bayer
And the two alumni mentors who were selected to mentor the project are:
– Elena Ivanchenko from Regeneron
– Stefano Scarafiotti from Inpeco
It is important to mention that Rosetta Omics was born at ESCP as I built the Business plan during my ICP project between May 2022 and May 2023, just two months after I started the startup project on March 2022. I proposed and led the business plan development project with a great team made of my friends and advisory board members:
Etienne Rutily, MBA Georges Kalouche Ana María Moreno Fernández Moheb KARKERA and it was supervised by prof. Saulpic Olivier and mentored by my friend and a healthcare KOL & EMBA alumni Vincent Malaterre

Rosetta Omics is among the AI for Health French Startups Mapping 2024.
We are very happpy to be in this panorama of the French innovative healthcare ecosystem.
This 3rd edition of the AI for Health Startups Mapping brings an updated vision of the sector with 191 key players in 10 categories : Medical Imaging, Monitoring & Telehealth, Patient Pathway, Data Foundations & Governance, Predictive Health & Early Diagnosis, Health Logistics, Medication Intelligence, Research, Robotics and Cybersecurity.

Rosetta Omics is expanding with the brightest minds in oncology! As we develop solutions that support pathologists, oncologists, and surgeons, collaboration with these professionals is crucial. Their insights ensure that our innovations truly meet the needs and expectations of those on the frontlines of cancer diagnosis and treatment. We have been incredibly impressed and inspired by the enthusiasm and keen insights these experts have shown toward our innovation. One standout contributor is Dr. Mohamed Amine Bani from Gustave Roussy, whose expertise and dedication are helping us reach more specialists/physicians and, ultimately, more patients.

We are honored to welcome Dr. Antoine Hollebecque, M.D., to our Scientific Advisory Board!

Dr. Hollebecque is a senior medical oncologist at the world-renowned Gustave Roussy Cancer Center in Paris and a leading expert in drug development and precision medicine. With over 15 years of experience in oncology, his contributions to the field are unparalleled.

🔬 Career Highlights:

* Principal investigator for 50+ Phase I/II/III clinical trials and a contributing investigator in 400+ trials in the past decade. * Extensive research in biliary and pancreatic carcinomas, FGFR inhibitors, and cell-free DNA during his post-doctoral fellowship at Cancer Research UK Manchester Institute. * Published 230+ peer-reviewed articles in leading journals, including @New England Journal of Medicine, Nature Medicine, and Cancer Discovery. 🌟 Global Recognitions: Dr. Antoine Hollebecque is an active member of ESMO – European Society for Medical Oncology, American Society of Clinical Oncology (ASCO), and the French Federation of Gastrointestinal Oncology (FFCD), and his work continues to shape the future of oncology research.

🚀 Big News Update from Rosetta Omics! 🎉
We’re thrilled to share that our collaborative efforts have paid off as we join forces with esteemed partners in a groundbreaking €1.5 million project focused on early detection and diagnosis of osteoarthritis! 💡
https://lnkd.in/eAYzZaaz
Although Rosetta Omics is primarily focused on precision oncology (digestive cancers), we’re excited to broaden our horizons and contribute to this vital research endeavor. Our partnership with Maastricht University, along with a stellar consortium including INIBIC Osteoarthritis Foundation, RIVM National Institute for Public Health and the Environment, and others, underscores our commitment to driving innovation beyond traditional boundaries.
The KIC call, ‘Early detection of osteoarthritis – Innovations for detection and diagnosis,’ backed by NWO and the Dutch Arthritis Society, aims to revolutionize osteoarthritis management.
By developing cutting-edge diagnostic tools and predictive biomarkers, we’re paving the way for early intervention and personalized treatment pathways.
With 1.5 million people currently affected by osteoarthritis in the Netherlands alone, the urgency of our mission cannot be overstated. Through interdisciplinary collaboration and innovative technologies like artificial intelligence, we’re poised to make a tangible impact on healthcare outcomes and quality of life for millions worldwide.
This project, aptly named CircBioCare:
Circulating epigenetic and protein biomarkers for early OA diagnosis in primary care and patient stratification, marks just the beginning of Rosetta Omics‘ journey in European collaborative projects. We’re honored to be at the forefront of this critical research initiative, driven by our shared vision of ‘Living longer in good health.’
Thank you to all our partners, collaborators, and supporters who make endeavors like these possible. Together, we’re shaping the future of healthcare one breakthrough at a time! 🌟
Thank you Berta Cillero Pastor for leading this effort and for iviting us to this project and we are looking forward to working with you and all other partners:
INIBIC Osteoarthritis Foundation International – OAFI Susan Picavet RIVM National Institute for Public Health and the Environment QIAGEN Olink Proteomics Thomas Morsch Covaris Bram Snijders Bruker Nicolas Autret, PhD Pieter Emans MERLN Institute for Technology-Inspired Regenerative Medicine Maastricht University Maastricht UMC+ Alma Mingels Virginie Joris Robert van Gog @Francisco Blanco Martijn van Griensven @Annelies Boonen @Stephanie Fanucchi Agilent Technologies University of Antwerp UMC Utrecht @Paula de Galan

Our CEO Dr. Wahid Awad, Ph.D. MBA, participated in the entrepreneurship festival organized by ESCP Business School’s incubator Blue Factory ESCP, at the schools new campus in Champerret, Paris.
Dr. Awad had a booth and pitched Rosetta Omics in front of the festival attendees. The theme of the festival was «Open your Horizons”.
ESCP Business School is where Dr. Awad finished his executive MBA program where he studied in its campuses in Paris, London, Berlin, Turin and Madrid. In addition to its partnering schools in the USA, Brazil and Lebanon.
ESCP Business School executive MBA program is ranked as world’s number 3 by the Financial Times in 2023.

Our CEO, Wahid Awad was honored to be invited by professor Vittorio De Pedys, professor of finance at ESCP Business School to talk about entrepreneurship in the biopharmaceutical field and about Rosetta Omics at the Grenoble Ecole de Management in Paris.
The course was part of the Advanced Master in Biomedical Management (Bac + 6 Classement):
hashtag1er Master France pour la 4ème année consécutive & #6 Monde du classement Eduniversal 2023 des meilleurs Masters (120 étudiants pour l’année en cours).
It was great to see a very strong interest from the students in Rosetta Omics and to have some students who wants to help and work with Rosetta Omics after my lecture. This is a group of brilliant and curious pharma graduates who all work for pharma/biotech and medical device companies.

Dr. Dominique Bagnard

Member of the eSAC nETWORK

International Consulting Projects- Collaboration with ESCP Business School

Filière Intelligence Artificielle & Cancers

Completed our first Proof of Concept study in Colon Cancer

Executive Board Member at Medicen Paris Region!

Advisor Professor Magali Svrcek

Leonardo Cunha

HealthTech Conference By PROXIMUM 365

HealthTech Investor Summit

Completed a second proof of concept study (POC) in Colorectal cancer

RESI J.P. Morgan Healthcare week

Anne De Landsheer

Dr. Tanya Aneichyk

Advisor Dr. Hatem Azim

Membership and Partnership with France Biotech

International Consulting Projects- Collaboration with ESCP Business School

AI for Health French Startups Mapping

Advisor Dr. Mohamed Amine Bani

Advisor Dr. Antoine Hollebecque

partnership with Maastricht University

entrepreneurship festival by incubator Blue Factory ESCP

at the Grenoble Ecole de Management